Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarke...
Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience
About this item
Full title
Author / Creator
Publisher
Netherlands: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Netherlands: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Highlights ► The 32-year safety profile of M–M–R™II is described using data from postmarketing surveillance. ► Of ∼575 million doses distributed, 17,536 AEs were voluntarily reported (30.5 AEs/1 × 106 doses). ► This review provides evidence that the vaccine is safe and well-tolerated.
Alternative Titles
Full title
Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1272722820
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1272722820
Other Identifiers
ISSN
0264-410X
E-ISSN
1873-2518
DOI
10.1016/j.vaccine.2012.08.057
